Winrevair (sotatercept-csrk), compared to placebo, reduced the risk of all-cause death, lung transplantation, and hospitalization.

A team of pharmaceutical researchers at Novartis Biomedical Research, working with an international team of associates, has ...

IgniteData has announced a partnership with AstraZeneca, MSK for launching the Archer tool for automation of EHR-to-EDC in a ...

The Trump administration this week decimated HIV prevention programs across government health agencies after terminating ...

Research reveals how specific sleep stages protect brain vulnerable to Alzheimer's, offering hope through simple lifestyle ...

Initial results from the ongoing trial saw one patient achieving a complete response in the trial combining Tovecimig with ...

MIRA Pharmaceuticals, Inc. (NASDAQ:MIRA), a clinical-stage pharmaceutical company developing breakthrough therapeutics for neurologic and neuropsychiatric disorders, today announced the enrollment of ...

Toxicity information from phase 3 oncology clinical trials often is incomplete and interpreted in ways that minimize its ...

Carrillo, MD, evaluates the current state of the global availability of clinical trials for patients with renal cell ...

CNW/ - NetraMark Holdings Inc. (the "Company" or "NetraMark") (CSE: AIAI) (OTCQB: AINMF) (Frankfurt: PF0) a premier ...

IHL-42X is designed to treat OSA by targeting its underlying pathophysiology. An oral fixed-dose combination of dronabinol and acetazolamide, IHL-42X is currently advancing through the RePOSA Phase ...

Topline results were announced from a phase 3 trial evaluating Xyngari (formerly DMT310), a novel topical treatment derived ...